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Abstract
Determining the molecular mechanisms that lead to the development of heart failure will help us gain better insight into
the most costly health problem in the Western world. To understand the roles that the actin protein plays in the
development of heart failure, we have taken a systematic approach toward characterizing human cardiac actin mutants that
have been associated with either hypertrophic or dilated cardiomyopathy. Seven known cardiac actin mutants were
expressed in a baculovirus system, and their intrinsic properties were studied. In general, the changes to the properties of
the actin proteins themselves were subtle. The R312H variant exhibited reduced stability, with a Tm of 53.6uC compared to
56.8uC for WT actin, accompanied with increased polymerization critical concentration and Pi release rate, and a marked
increase in nucleotide release rates. Substitution of methionine for leucine at amino acid 305 showed no impact on the
stability, nucleotide release rates, or DNase-I inhibition ability of the actin monomer; however, during polymerization, a 2-
fold increase in Pi release was observed. Increases to both the Tm and DNase-I inhibition activity suggested interactions
between E99K actin molecules under monomer-promoting conditions. Y166C actin had a higher critical concentration
resulting in a lower Pi release rate due to reduced filament-forming potential. The locations of mutations on the ACTC
protein correlated with the molecular effects; in general, mutations in subdomain 3 affected the stability of the ACTC
protein or affect the polymerization of actin filaments, while mutations in subdomains 1 and 4 more likely affect protein-
protein interactions.
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Introduction
Heart failure is a major health problem among developed
nations and has been described as the emerging health epidemic of
the 21
st century [1]. Changes in protein interactions in
cardiomyofibre sarcomeres lead to abnormal heart function,
contributing to the development of heart diseases such as
hypertrophic cardiomyopathy (HCM) or dilated cardiomyopathy
(DCM) [2]. The understanding of the molecular mechanisms
involved in HCM and DCM development have grown beyond
early hypotheses that defective actomyosin force generation causes
HCM and altered force transmission leads to DCM [3]. We
believe that altered interactions between sarcomere proteins lead
to disease states through two related mechanisms: intrinsic
instability of the encoded protein, resulting in a reduced level of
active protein in the heart, or specific protein interaction changes
between the altered protein and binding partners.
To test this hypothesis, we are establishing if variants of the
fundamental cardiac actin protein (ACTC) exhibit changes in their
biophysical properties that may contribute to cardiomyopathy
development. Fourteen known mutants of human ACTC are
found in patients that suffer from DCM or HCM (Figure 1A [4–
9]). Given the often late onset of symptoms, changes in actin
activity resulting from these mutations are likely subtle or are
overcome by compensatory mechanisms like cardiac remodeling.
Nevertheless, it is important to understand the molecular
deficiencies associated with these naturally occurring mutants of
ACTC as a starting point for understanding the mechanisms
underlying the development of heart diseases.
Actin is a 42 kDa protein that is made up of 2 domains and held
in its native state by a metal-coordinated nucleotide between the
domains. Actin monomers self-associate to form filaments (F-actin)
that are an integral part of the muscle contractile machinery. Actin
inhibits DNase-I exonuclease activity through a surface loop called
the DNase-I binding loop (D-loop). During polymerization, this
loop inserts into a hydrophobic cleft in a neighbouring actin
protomer [10]. Mutations in this hydrophobic cleft affect actin
polymerization [11].
The proper folding of the actin protein requires the eukaryotic
chaperonin CCT complex [12]. In the absence of the CCT
complex, the unfolding of actin is considered an irreversible
process, connected with the loss of metal-coordinated nucleotide
from the nucleotide binding pocket. Several techniques have been
used to assess actin protein unfolding, including loss of activity
assays [13,14], changes in absorbance [15], differential scanning
calorimetry [16], and circular dichroism (CD) measurements [17].
In addition to establishing the protein folding and stability of
ACTC variants, we measured nucleotide exchange, polymeriza-
tion and intrinsic F-actin ATPase activities of the ACTC proteins.
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the biophysical properties of most ACTC variant proteins have
not been reported. Some mutations of ACTC associated with
cardiomyopathy development have been studied with in vitro
transcription/translation [18], in yeast actin (ACT1) [19], using
baculovirus expression[20–22], or in transgenic mouse models
[23,24].
While in vitro transcription/translation studies suggested reduced
native folding for E99K, P164A, M305L and E361G ACTC
variants [18], later work showed that purified P164A and E361G
ACT1 proteins from yeast polymerized in a manner similar to WT
ACT1 protein [19]. In vitro protein stability studies using
baculovirus-expressed E99K ACTC yielded contradictory results
suggesting that E99K ACTC was stable compared to WT ACTC,
with respective Tm values of 59.8uC and 60.5uC [20]. Purified
A331P yeast actin exhibited a lower Tm of 51.6uC compared to
60uC for the WT protein [19].
Previous work shows that the R312H mutation affects actin
protein stability, resulting in delayed protein folding by the CCT
complex [18] and the inability of viable protein to be purified from
yeast [19]. On the other hand, R312H ACTC protein could be
successfully purified using baculovirus expression [22]. While this
protein forms filaments, the properties of purified R312H ACTC
protein were not reported. Similarly, the biophysical properties of
E99K and E361G ACTC proteins stably-expressed in transgenic
mice were not studied. Resolving some of the conflicting results
from previous work was part of our motivation for this study.
No other detailed biophysical information exists regarding the
effects of the remaining mutations of ACTC on the actin protein,
to the best of our knowledge. As a step toward filling the gap in
knowledge regarding the ACTC variants found in patients with
HCM or DCM, we have determined if seven ACTC variant
proteins possess significantly different intrinsic biophysical and
polymerization properties than wildtype ACTC protein. The
seven ACTC variants were selected based on the chronology of
their discovery in human patients; these were seven of the first nine
variants to be discovered that were successfully produced with
baculovirus in our laboratory. The A331P and R312H ACTC
variants showed stability defects, while the M305L ACTC protein
exhibited a fast inorganic phosphate release rate during polymer-
ization. The E99K ACTC protein displayed a Tm much greater
than WT ACTC that could be reduced to a level similar to WT by
modification with tetramethylrhodamine, suggesting the formation
of intermolecular contacts under monomer-promoting conditions.
Finally, the Y166C ACTC protein displayed polymerization
defects, confirming the hypothesis that this region of actin is
involved with F-actin interactions. Based on the locations and
effects of the mutations, we concluded that ACTC variations in
subdomain 3 of the actin molecule affect intrinsic stability and/or
actin polymerization while mutations in subdomains 1 or 4 do not
affect intrinsic actin properties and their role in the development of
heart disease is more likely a result of altered interactions with
other sarcomere proteins.
Results
There are fourteen variants of human cardiac actin found in
patients with DCM or HCM. Determining the molecular
deficiencies associated with the naturally occurring mutants of
ACTC is an important starting point for understanding the
mechanisms of heart disease development. We purified seven of
the first ACTC mutants to be discovered using a baculovirus
expression system (Figure 1B) and characterized their biophysical
properties to determine the effect of these mutations on ACTC
function (Table 1).
Protein Stability
The thermal stability of a protein reflects its ability to be
properly folded and remain in a native state. For actin, the
Figure 1. Cardiac actin mutations related to cardiomyopathies.
A. The protein structure of actin (PDB 1J6Z) [39] showing the locations
of mutations related to HCM (in green spacefilling) or DCM (in red
spacefilling) and bound ATP (sticks) visualized using PyMol [40]. The D-
loop of actin is highlighted with a dashed circle. ACTC substitution
mutations related to HCM shown are: H88Y, F90del, R95C, E99K, P164A,
Y166C, A230V, S271F, A295S, R312C, A331P, and M305L. The two ACTC
mutants associated with DCM are R312H and E361G. The amino acid
numbers listed are based on the sequence of the protein after
posttranslational processing of the N-terminus, which removes the first
two amino acids of the nascent polypeptide. Note that mutations at
Arg-312 are associated with both HCM and DCM. B. Purification of
baculovirus expressed ACTC mutant protein. Sf9 cells were infected
with recombinant baculovirus expressing the A230V ACTC mutant
protein at an MOI of 1 for 72 hours. Shown is a 10% SDS-PAGE of
samples taken throughout the purification: lane 1, crude lysate; lane 2,
supernatant fraction of lysates; lane 3, lysate following filtration and
applied to a DNase-I affinity column; lane 4, purified A230V ACTC
protein eluted from the DNase-I affinity column. Arrows indicate the
position of actin and the polyhedrin protein expressed by the
baculovirus in Sf9 cells.
doi:10.1371/journal.pone.0036821.g001
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protein stability [13,15]. We measured the melting temperature of
Ca.ATP-bound ACTC variants employing CD at a scan rate of
1uC per minute. The R312H variant possessed the lowest Tm of
the ACTC proteins, supporting findings of instability with this
mutation generated using yeast actin [19] and an in vitro
transcription/translation system [18].
Interestingly, E99K ACTC protein possessed a significantly
higher Tm of 68.8uC compared to the other ACTC proteins
(Figure 2A). Since the melting temperature of F-actin is around
67uC [25], we wondered if E99K ACTC might be forming F-actin
like contacts even under conditions that are generally known to
promote dispersed actin monomers. To test this hypothesis, we
modified E99K ACTC with tetramethylrhodamine to inhibit actin
polymerization [26,27]. Using CD, a Tm for TMR-E99K ACTC
of 56.7uC was determined, similar to that of WT ACTC,
suggesting that some E99K ACTC self-interactions may occur
under conditions that are generally known to promote monomeric
actin.
The ability of actin to inhibit DNase-I activity reflects the
number of available DNase-I binding sites in a sample of actin
[14]. Generally, it is considered that unfolded actin aggregates do
not bind DNase-I and therefore, DNase-I inhibition is often used
to infer the proportion of folded and unfolded actin within a
sample [20]. Other factors such as mutations within the D-loop or
actin-actin interactions are also known to impact the ability of the
actin protein to inhibit DNAse-I activity [28,29]. As a result,
DNase-I inhibition measures the proportion of monomeric folded
actin in a sample and the effect of mutation on DNase-I binding.
If a mutation on actin does not affect the binding of DNase-I,
there should be a correlation between DNase-I IC50 and actin Tm.
When we plotted Tm values of the ACTC variants against
measured DNase-I IC50 values, five of the ACTC proteins,
including WT ACTC, fell on a fitted single exponential decay
curve (Figure 2B), suggesting that the amino acid substitutions in
these ACTC proteins do not affect their interactions with DNase-I.
The R312H ACTC mutant protein had the highest DNase-I IC50
value measured one day after purification (Figure 2D). After two
days, the R312H ACTC IC50 values increased, suggesting a
higher proportion of unfolded protein. Conversely, WT ACTC
protein exhibited a relatively constant DNase-I IC50 over the same
period, suggesting that it remains unchanged (Figure 2C).
Three ACTC variants deviated from the observed correlation
between Tm and DNase-I IC50: E99K and A331P ACTC proteins
both had Tm and DNase-I IC50 values higher than WT ACTC,
while A230V ACTC had a DNase-I IC50 value similar to WT
ACTC but with a much lower Tm. It is likely that the mutations of
these ACTC variants affect the measurements of Tm and DNase-I
IC50 disproportionately. For E99K ACTC, the 2-fold increase in
the DNase-I IC50 of E99K ACTC compared to WT ACTC
suggests that half of the D-loops are inaccessible to DNase-I,
perhaps as a result of interactions between the actin monomers
suggested above. A similar mechanism may account for the 2-fold
increase in IC50 for A331P ACTC. On the other hand, a
mechanism explaining the low Tm and normal DNase-I IC50 for
A230V ACTC is not clear, but may involve local structural
instability that does not affect the D-loop as a result of the
mutation.
Nucleotide Interactions
Actin proteins bind a molecule of metal-coordinated ATP in
their nucleotide-binding pocket. The hydrolysis of ATP occurs at a
higher rate in F-actin, followed by the release of inorganic
phosphate (Pi). Defects in nucleotide binding or the ability to
hydrolyze ATP might contribute to defects in protein stability or
the regulation of actin filaments in vivo.
The rate of nucleotide release from all of ACTC proteins tested
under monomeric actin conditions fitted a 2
nd order decay model
(Figure 3) with a slow and fast rate occurring. We found no
statistical difference between the slow nucleotide release rates for
the ACTC mutants. The different decay curves for the R312H
ACTC mutant revealed significantly different fast release rates
compared to the other ACTC proteins (Table 1).
Three classes of Pi release rates emerged from analysis of the
ACTC mutant proteins under polymerizing conditions
(Figure 4A): those similar to WT (E99K and A230V), those with
significantly lower Pi release rates (Y166C, E361G, and A331P),
and those with significantly higher Pi release rates (M305L and
R312H). The R312H ACTC mutant had the highest rate of
nucleotide release under non-polymerizing conditions and the
Table 1. Summary of the intrinsic properties of ACTC mutant proteins related to the development of cardiomyopathies in
humans.
Tm DNase-I Nucleotide Release Cc Pi Release
ACTC (6C) IC50(nM) Slow Rate (ms
21) Fast Rate (ms
21)( mM) (s
21610
22)
WT 56.861.3 13.2 1.1262.64 17.4767.40 0.2860.13 1.2460.02
E99K 68.860.35* 25.7 2.2462.18 17.7365.76 1.6760.43* 1.2560.02
56.760.23
{
Y166C 54.161.9 24.6 1.6260.61 16.0164.56 2.6760.45* 0.3860.02*
A230V 53.961.9 15.3 2.0260.42 16.2564.16 2.1161.23 1.5160.24
M305L 55.561.7 17.0 2.2161.94 18.2361.61 2.2161.78 2.4360.03*
R312H 53.662.0 36.7 8.8765.52 181.86140.7** 4.7560.27* 2.5960.05*
A331P 57.460.23 26.0 3.6364.21 22.7569.05 2.9561.70 0.8860.06*
E361G 55.661.7 16.8 2.0661.35 18.1162.97 0.5860.48 0.6660.05*
{labeled with tetramethylrhodamine.
*p,0.05 by t–test.
**p,0.15 by t–test.
All values are the average of at least three replicates, showing the standard deviation of each.
doi:10.1371/journal.pone.0036821.t001
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Pi release rate during polymerization of R312H ACTC is likely
due to breakage of filaments, resulting in rapid treadmilling and
ATP hydrolysis, as seen with other unstable mutant actin proteins
[30,31]. Conversely, the Y166C ACTC protein had the lowest
nucleotide release and Pi release rates, suggesting a defect in
polymerization.
Polymerization Properties
To determine the impact of ACTC mutations on the ability of
the proteins to polymerize, we measured the critical concentra-
tion (Cc) for all of the ACTC variants. We found the R312H,
A331P and Y166C ACTC mutants possessed the highest Cc
values of the ACTC mutants, reflected in lower maximum F-
actin content in polymerization reactions (Figure 4B). When
ultrastructural details were examined by electron microscopy, we
found all of the ACTC mutants formed filaments with normal
morphology, except Y166C ACTC. The Y166C mutant ACTC
protein did not form regular actin filaments, but rather short
filaments and aggregates (Figure 4C), confirming a polymeriza-
tion defect.
Figure 2. Intrinsic cardiac actin mutant monomer properties. A. The melting temperature of WT ACTC (N) (black circle) was similar to that of
TMR-modified E99K ACTC (N) (grey circle) (56.861.3uC and 56.760.23uC, respectively). Unmodified E99K ACTC (O) had a melting temperature of
68.860.35uC. B. Correlation of measured Tm and DNase-I IC50 values. The values for five of the tested ACTC proteins fitted a single exponential decay
equation (y= y0+Ae
-bx, where y0 was 53.460.15, A was 19.2762.65, and b was 0.13160.01 (S.E.)) with an R
2 of 0.998). Both ACTC variants with
measured Tm values higher than WT displayed higher DNase-I IC50 values (E99K ACTC is not shown), while the A230V ACTC displayed a lower Tm
value with an IC50 similar to WT ACTC. C. DNase-I inhibition curves with WT ACTC protein show little change over time (day 2, O; day 5, ?; day 7, ,).
Data points are averages of triplicate measurements, with error bars showing standard deviation. D. DNase-I inhibition by R312H ACTC protein shows
a higher initial IC-50 value (day 2, ?). At day 7 (O), the IC50 data could not be fitted because it had increased.
doi:10.1371/journal.pone.0036821.g002
Figure 3. Nucleotide release from monomeric ACTC variant
proteins. The release of e-ATP from WT ACTC followed a 2
nd-order
decay model (N). The R312H ACTC protein showed faster nucleotide
release kinetics (O) that fitted the 2
nd-order decay model with a
significantly different fast decay rate.
doi:10.1371/journal.pone.0036821.g003
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At the core of the heart muscle are contractile proteins. We have
sought to understand some of the mechanisms of heart failure from
the perspective of the cardiac actin protein. While changes to
interactions between some ACTC variants and specific proteins
have been studied, very little is known about the biophysical
properties of naturally occurring ACTC mutants related to heart
disease themselves.
When the ACTC mutants were ranked within each assay, two
main groups were observed: those ACTC mutants with changes in
actin protein stability and those with changes in actin protein
polymerization. However, it should be noted that the magnitudes
of any changes in these ACTC mutant proteins were subtle. These
subtle changes might reflect the late development of some HCM
or DCM cases in humans.
We observed a strong correlation between Tm values and
DNase-I IC50 values for five of the ACTC proteins examined.
However, for E99K and A331P ACTC, intermonomer interac-
tions may bury some of the D-loops of ACTC, resulting in
disproportionate changes in the two parameters. This is most likely
the case for E99K ACTC, where modification with TMR reduced
an elevated Tm reminiscent of F-actin to that of monomeric WT
ACTC. It is not clear if such interactions would impact the heart,
since actin filaments form for both E99K and A331P ACTC
proteins and a host of regulatory proteins surround the actin
filament in situ to encourage proper filament structure.
Our rankings suggested a pattern where intrinsic deficiencies
occur with mutations in subdomain 3 of actin (Figure 5, R312H,
A331P and Y166C) while mutations in subdomains 1 and 4 do not
affect the intrinsic properties of the actin, but more likely affect
protein-protein interactions. The Y166C ACTC mutant exhibited
polymerization deficiency through an increased Cc, abnormal
filament morphology, and lowered Pi release. This mutation is
located in the hydrophobic cleft of actin which is known to be
involved in F-actin contacts [10]. Similarly, studies on yeast actin
show that mutations within the W-loop (a.a. 165–172) of yeast
actin also impact actin polymerization. [11].
The R312H ACTC mutant possessed reduced protein stability
accompanied with higher polymerization Cc, and increased
Figure 4. Properties of ACTC mutant proteins under polymerization conditions. A. Polymerization of 10 mMW T(N), R312H (O), and Y166C
(.) ACTC proteins in the presence of polymerization salts and 2.5% pyrene-actin. 20% of the data is shown for clarity. B. Phosphate release of WT (N),
R312H (O), Y166C (.), and M305L (n) ACTC proteins under polymerization conditions in the presence of 0.1 mM ATP. Upon the addition of
polymerization salts, the release of inorganic phosphate was measured and the total concentration plotted over time. Data points are averages of
triplicate measurements, with error bars showing standard deviation and linear regression of the data to determine the specific activity of each ACTC
protein. C. Electron microscopy of WT ACTC and mutant proteins, following a 2 hour incubation at room temperature in the presence of
polymerization buffer. Note the absence of filaments in the Y166C ACTC protein sample. Images are representative of each ACTC mutant protein
shown. Scale bar, 100 nm.
doi:10.1371/journal.pone.0036821.g004
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phosphate during polymerization of R312H ACTC is likely due to
breakage of filaments, resulting in rapid treadmilling and ATP
hydrolysis, as seen with other unstable mutant actin proteins
[30,31]. These observations are confirmed by previous work
showing the effect of the R312H mutation on actin protein
stability [18,19,32]. Altered contractile protein interactions were
observed with reconstituted regulated R312H ACTC filaments
leading to increased calcium sensitivity [22,33]. It is not clear how
instability of the R312H ACTC variant is related to changes in
protein interactions; however, the inclusion of the filament
stabilizing toxin phalloidin to the assays may have influenced the
behaviour of the variant ACTC protein.
The A331P ACTC mutant also follows a pattern of altered
protein stability, but with less severity. Ala-331 is located in
subdomain 3 of actin, beside Pro-332 and Pro-333 in the hinge
region between the large and small domains [34]. The addition of
another Pro residue results in faster nucleotide release rates,
supporting the hypothesis that movement of this region is critical
for nucleotide binding [35,36]. A331P ACTC protein also
displayed a relatively high F-actin Cc and a slow inorganic
phosphate release rate, suggesting a slight defect in polymeriza-
tion., something that was seen with A331P yeast actin [19]. The
yeast actin A331P protein Tm of 51.6uC as measured by CD [19]
also agrees with the hypothesis that A331P ACTC is structurally
unstable. However, the A331P ACTC protein showed a Tm higher
than WT ACTC protein. Intermonomer interactions similar to
those likely occurring E99K ACTC may also occur with A331P
ACTC to affect the Tm and DNase-I IC50.
Aside from potential intermolecular interactions of E99K
ACTC protein under monomeric conditions, ACTC mutations
in subdomain 1 of actin (E99K and E361G) did not otherwise
adversely affect the intrinsic properties of the actin molecule itself
and more likely affect protein interactions. Previous work has
shown that the E99K mutation affects myosin and tropomyosin
binding [20,22], while the E361G mutation affects a-actinin
binding [19] and the regulation of actin filaments by troponin I
[23].
The locations of both A230V and M305L mutations in
subdomain 4 are not thought to be involved in important F-actin
contacts or actomyosin interactions. The increase in Pi release rate
of M305L ACTC protein may reflect the location of the mutation
within the nucleotide-binding cleft [34]. The A230V ACTC
mutation is believed to be in the tropomyosin-binding site [37].
Based on the pattern emerging from our data, we predict that
the remaining ACTC mutations located in subdomain 3 (P164A,
S271F, A295S, and R312C) affect protein stability or actin
polymerization, while mutations in subdomain 1 (H88Y, F90del,
R95C) impact protein interactions with other sarcomere proteins.
We can now examine the interaction of the ACTC proteins with
important actin binding proteins, including myosin, thin filament
regulatory proteins, and myosin binding protein-C to test our
model and further illuminate the molecular alterations that occur
with changes in the ACTC protein that are related to the
development of cardiomyopathies.
Materials and Methods
Reagents
Unless otherwise stated, all reagents were purchased from either
Sigma-Aldrich (St. Louis, MO) or Fisher Scientific (Mississauga,
ON).
Recombinant Baculovirus Generation
The E99K-ACTC mutant and WT ACTC recombinant viruses
had previously been produced [21]. ACTC point mutants leading
to amino acid substitutions R312H, E361G, P164A, A331P,
Y166C, A295S, A230V and M305L were produced in the human
ACTC cDNA using the one-step Quikchange site-directed
mutagenesis system (Stratagene, La Jolla, CA) with oligonucleo-
tides containing BamHI restriction sites at the 59 and 39 ends and
subcloned into the pTOPO2 vector using TOPO-TA cloning
(Invitrogen, Carlsbad, CA). The mutant ACTC DNA was
subsequently BamHI digested out of the TOPO vector and ligated
into BglII digested pAcUW2Bmod vector. The orientation of the
insert, mutagenesis, and absence of other PCR-induced errors
were verified by direct DNA sequencing.
Recombinant viruses were produced by co-transfecting Sf9
insect cells with the pAcUW2Bmod mutant-ACTC constructs and
linearized baculovirus DNA in the presence of Bacfectin
(Clontech, CA). The presence of the ACTC cDNA in the
amplified recombinant viruses was verified by PCR and the viruses
were plaque-purified as previously described [21].
Purification of ACTC Proteins
Approximately 1610
9 Sf9 cells infected at a multiplicity of
infection (MOI) of 1 with recombinant baculovirus were harvested
at 72 h post-infection by centrifugation and the ACTC mutant
protein was purified as described [21], with the addition of the
cleared cell lysates being passed through glass wool twice to
remove residual cell debris and lipids before purification by
DNase-I affinity chromatography. Purified actin was concentrated
with an Amicon concentrator 10,000 MWCO (Millipore, Billerica,
MA) and protein concentration determined with Bio-Rad Protein
Assay dye reagent (Bio-Rad, Hercules, CA) employing purified a-
skeletal G-actin as a standard. The purity of the protein was
checked by SDS-PAGE and then stored at 4uC. Tetramethylrho-
Figure 5. Correlation of location and effects of ACTC muta-
tions. The locations of ACTC mutations associated with cardiomyop-
athies are shown in black (HCM) and red (DCM) letters. The regions of
molecular effects are circled and spacefilling models presented in red
(protein stability changes), green (actin polymerization changed), and
blue (no significant intrinsic property changes). Those residues shown
in grey have not been characterized. Coordinate data for ATP-bound
TMR-actin (1J6Z) [39] were visualized using PyMol [40].
doi:10.1371/journal.pone.0036821.g005
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out using established methods [15].
Pyrene-actin Polymerization Assays
The polymerization of each ACTC mutant was assessed with a
pyrene-fluorescence-based assay [38]. Briefly, actin samples in G-
buffer (2 mM Tris, pH 8.0, 0.2 mM CaCl2, 0.2 mM ATP,
0.5 mM bME) were mixed with 2.5% pyrene-labeled a-skeletal
actin and the fluorescence monitored before and after addition of
polymerization buffer (25 mM Tris, pH 8.0, 50 mM KCl, 1 mM
EGTA, 2 mM MgCl2 and 0.1 mM ATP final concentration) in a
Varian Cary Eclipse fluorometer (Varian Inc, Walnut Creek, CA)
with excitation and emission wavelengths set at 347 nm and
407 nm respectively and the slit width at 2.5 nm for the excitation
and 5 nm for the emission. The critical concentration was
determined as the x-intercept of the linear regression derived
from fitting the change in pyrene-fluorescence (y-axis) from each of
the polymerization profiles of different actin concentrations (x-axis)
using the statistical software SigmaPlot 11 (Systat software Inc, San
Jose, CA).
DNase-I Inhibition
The folding and stability of the purified ACTC proteins were
assessed using a high throughput DNase-I inhibition assay as
described previously [14]. Briefly, 0 to 100 nM ACTC protein and
15.4 nM DNase-I in G-buffer were incubated in 50 ml reactions
for 30 min at room temperature in a UV transparent 96 well
microplate (Corning Inc., Corning, NY). The assay was initiated
by adding 200 ml of 240 mg/ml salmon sperm DNA prepared in
DNA buffer (100 mM Tris pH 8, 4 mM MgCl2, 1.8 mM CaCl2)
in each well of the plate. The absorbance was immediately
monitored at 260 nm over a period of 3 min using a UV plate
reader (BioTek, Winooski, VT). The percentage of DNase-I
activity was determined by comparing the initial linear rates of
DNase-I activity in assays containing ACTC to control reactions
containing no actin. The IC50 of DNase-I by ACTC was
determined as the concentration of the ACTC protein that causes
50% inhibition of DNase-I activity. DNase-I activity plots were
generated using SigmaPlot 11 (Systat Software, San Jose, CA).
Thermal Stability
The thermal stability of ACTC samples was determined using
circular dichroism (CD) spectrometry. ACTC samples were
dialyzed in HEPES G-buffer (2 mM HEPES, pH 8.0, 0.2 mM
CaCl2, 0.2 mM ATP, and 0.2 mM bME) with at least 3 buffer
exchanges. Following dialysis, the concentrations of the actin
samples were determined using the Bio-Rad Protein Assay dye
reagent (Bio-Rad, Hercules, CA) with purified a-skeletal G-actin
as a standard and the proteins were diluted to 0.16 mg/ml in
HEPES G-buffer. The negative ellipticity of the actin protein
samples was measured at 222 nm with an increasing thermal
gradient from 20–85uCa ta1 uC/min scan rate using a JASCO J-
815 Chiro-optical spectrometer (JASCO, Easton, MD). The rate
of change in ellipticity at 222 nm was plotted as a function of
temperature, a Weibull fit was applied using SigmaPlot 11 (Systat
Software, San Jose, CA), and the minimum was taken to be the
melting temperature (Tm), as described previously [15].
Pi Release
The inorganic phosphate released from actin samples upon the
initiation of polymerization was monitored using the EnzChek
phosphate assay kit (Invitrogen, Burlington, ON). Reactions
(250 ml) containing 10 mM ACTC in G-buffer, 400 mM MESG,
and 0.5 U purine nucleoside phosphorylase were incubated for
15 min at room temperature before polymerization to remove any
inorganic phosphate present in solution. Following incubation,
polymerization salts were added to a final concentration of 50 mM
KCl and 2 mM MgCl2 to initiate polymerization and the
absorbance at 360 nm monitored using a Beckman Coulter
DU800 spectrophotometer (Beckman, Mississauga, ON). Mea-
surements in the absence of MESG were baseline-subtracted from
the experimental data to account for light scattering of polymer-
izing actin samples. A standard curve of 0 to 100 mM inorganic
phosphate was used to convert absorbance at 360 nm to inorganic
phosphate concentration. Phosphate release rates were plotted
using SigmaPlot 11 (Systat Software, San Jose, CA).
Nucleotide Release
The rates of e-ATP release from ACTC proteins were
determined by the change in the fluorescence of e-ATP-bound
ACTC using a stopped-flow fluorometer. Unbound ATP was
removed from 10 mM ACTC in G-buffer containing 10 mM Tris-
HCl, pH 8.0, using Bio-Rad AG 1-X8 anion exchange resin
(Hercules, CA) equilibrated in the same buffer. Following removal
of unbound ATP, 0.1 mM e-ATP was added and incubated on ice
at 4uC for 2 h. Unbound e-ATP was then removed using Bio-Rad
AG 1-X8 anion exchange resin (Hercules, CA) equilibrated in G-
buffer containing 10 mM Tris-HCl, pH 8.0. 10 mM e-ATP was
then added to the solution and the actin concentration determined
using Bio-Rad Protein Assay dye reagent (Bio-Rad, Hercules, CA)
employing purified a-skeletal G-actin as a standard. Prior to use in
the experiment, e-ATP-bound ACTC proteins were diluted to
2 mM using G-buffer containing 10 mM Tris-HCl, pH 8.0, and
10 mM e-ATP.
2 mM e-ATP-bound ACTC proteins were rapidly mixed with
an equal volume of G-buffer containing 10 mM Tris-HCl,
pH 8.0, 0.2 mM CaCl2, 0.2 mM ATP, and 0.2 mM bME, at
22uC using an Applied Photophysics SX20 stopped-flow fluorom-
eter (Applied Photophysics Ltd., Surrey, UK) with an excitation
wavelength of 350 nm, excitation slit width of 4.65 nm, and a
395 nm emission cutoff filter. The assay was performed in at least
triplicate for each ACTC-mutant protein per preparation. The e-
ATP fluorescence decay signal for ACTC-mutant proteins was
plotted against time and was fitted to a second order decay fit
using SigmaPlot 11 (San Jose, CA) to determine the nucleotide
release rates.
Electron Microscopy
Electron micrographs of the ACTC polymerization reactions
were taken to examine the morphology of the filaments. 10 mMo f
the actin proteins were incubated for 2 h at room temperature
under polymerization conditions. 3 ml of the polymerization
reactions were immobilized on carbon-coated grids and the grid
subsequently negatively stained with 2% aqueous uranyl acetate.
Filaments were viewed with a Leo 912ab
TM electron microscope
with an in-column Omega energy filter in the Microscopy Imaging
Facility at the University of Guelph.
Statistical Analysis
The statistical significance of the critical concentration, melting
temperature and inorganic phosphate release values for the ACTC
mutants compared to WT ACTC were evaluated by a t-test
(a=0.05) using GraphPad Software, Inc. (La Jolla, CA). To
understand the statistical significance of each ACTC mutant
nucleotide release rate, a Grubb’s test (at 95% confidence interval)
was used to identify outlying data points for each ACTC protein
tested. The means of the remaining data points are reported and
Cardiac Actin Mutations and Functional Changes
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a t-test (a=0.15).
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